Earnings Call · Q4 FY2023·2024-03-20

Q4 23EPS +12.90%·Rev n/aQ3 23EPS +2.70%·Rev n/aQ2 23EPS +11.90%·Rev n/aQ1 23EPS +23.26%·Rev n/a⚠ consensus missing

Rani Therapeutics Holdings, Inc. RANI

Kiki Patel

Talat Imran — Chief Executive Officer

Arvinder Dhalla — VP of Clinical Development

STELARA

Svai Sanford — Chief Financial Officer

+0.8%1d on move date+0.5% vs SPY3d−9.4%5d−15.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RANI calls or request research access.

More RANI calls Browse calls Request research access